Search

Your search keyword '"Moritz Biener"' showing total 3 results
Start Over Author "Moritz Biener" Publisher mdpi ag
3 results on '"Moritz Biener"'

1. Low-Level Elevations of Procalcitonin Are Associated with Increased Mortality in Acute Heart Failure Patients, Independent of Concomitant Infection

Author

Fabrice F. Darche, Moritz Biener, Matthias Müller-Hennessen, Rasmus Rivinius, Kiril M. Stoyanov, Barbara R. Milles, Hugo A. Katus, Norbert Frey, and Evangelos Giannitsis

Subjects
AHF, PCT, NT-proBNP, all-cause mortality, Science
Abstract

We aimed to evaluate the prognostic value of procalcitonin (PCT) in acute heart failure (AHF) patients, especially in those without underlying infection. We enrolled patients presenting with acute dyspnea to the emergency department (ED) of Heidelberg University Hospital and studied the prognostic role of PCT on all-cause death. Of 312 patients, AHF was diagnosed in 139 patients. Of these, 125 patients had AHF without signs of infection, and 14 had AHF complicated by respiratory or other infection. The optimal prognostic PCT cutoff value for mortality prediction was calculated by a receiver operating characteristics curve. In patients with AHF, the prognostic PCT cutoff value was 0.08 ng/mL. The Kaplan–Meier survival analysis showed that AHF patients with PCT values > 0.08 ng/mL had a higher all-cause mortality at 120 days than those with PCT values ≤ 0.08 ng/mL (log-rank p = 0.0123). Similar results could be obtained after subdivision into AHF patients with and without signs of overt infection. In both cases, mortality was higher in patients with PCT levels above the prognostic PCT cutoff than in those with values ranging below this threshold. Moreover, we show that the prognostic PCT cutoff values for mortality prediction ranged below the established PCT cutoff for the guidance of antibiotic therapy. In conclusion, the data of our study revealed that low-level elevations of PCT were associated with an increased mortality in patients with AHF, irrespective of concomitant respiratory or other infection. PCT should thus be further used as a marker in the risk stratification of AHF.

Published
2021
Full Text
View/download PDF

2. Peptide YY (PYY) Is Associated with Cardiovascular Risk in Patients with Acute Myocardial Infarction

Author

Evangelos Giannitsis, Marcia Viviane Rückbeil, Mohammad Almalla, Moritz Biener, Nikolaus Marx, J. Schroeder, Julia Moellmann, Florian Kahles, Michael Lehrke, Elias Haj-Yehia, Matthias Rau, R W Mertens, and Hugo A. Katus

Subjects
cardiovascular risk, medicine.medical_specialty, Renal function, lcsh:Medicine, 030209 endocrinology & metabolism, Disease, 030204 cardiovascular system & hematology, Article, 03 medical and health sciences, 0302 clinical medicine, Diabetes mellitus, Internal medicine, Medicine, Myocardial infarction, cardiovascular diseases, PYY, business.industry, Proportional hazards model, Confounding, digestive, oral, and skin physiology, lcsh:R, General Medicine, medicine.disease, mortality, myocardial infarction, Peptide YY, Heart failure, Cardiology, business, hormones, hormone substitutes, and hormone antagonists, gut hormone
Abstract

Aims: Recent studies have found circulating concentrations of the gastrointestinal hormone GLP-1 to be an excellent predictor of cardiovascular risk in patients with myocardial infarction. This illustrates a yet not appreciated crosstalk between the gastrointestinal and cardiovascular systems, which requires further investigation. The gut-derived hormone Peptide YY (PYY) is secreted from the same intestinal L-cells as GLP-1. Relevance of PYY in the context of cardiovascular disease has not been explored. In this study, we aimed to investigate PYY serum concentrations in patients with acute myocardial infarction and to evaluate their association with cardiovascular events. Material and Methods: PYY levels were assessed in 834 patients presenting with acute myocardial infarction (553 Non-ST-Elevation Myocardial Infarction (NSTEMI) and 281 ST-Elevation Myocardial Infarction (STEMI)) at the time of hospital admission. The composite outcomes of first occurrence of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke (3-P-MACE), and all-cause mortality were assessed with a median follow-up of 338 days. Results: PYY levels were significantly associated with age and cardiovascular risk factors, including hypertension, diabetes, and kidney function in addition to biomarkers of heart failure (NT-pro BNP) and inflammation (hs-CRP). Further, PYY was significantly associated with 3-P-MACE (HR: 1.7, 95% CI: 1&ndash, 2.97, p = 0.0495) and all-cause mortality (HR: 2.69, 95% CI: 1.61&ndash, 4.47, p = 0.0001) by univariable Cox regression analyses, which was however lost after adjusting for multiple confounders. Conclusions: PYY levels are associated with parameters of cardiovascular risk as well as cardiovascular events and mortality in patients presenting with acute myocardial infarction. However, this significant association is lost after adjustment for further confounders.

Published
2020

3. Prognostic Value of Elevated Copeptin and High-Sensitivity Cardiac Troponin T in Patients with and without Acute Coronary Syndrome: The ConTrACS Study

Author

Kiril M. Stoyanov, Mehrshad Vafaie, Hanna Waldsperger, Matthias Mueller-Hennessen, Moritz Biener, Hugo A. Katus, and Evangelos Giannitsis

Subjects
medicine.medical_specialty, Acute coronary syndrome, Cardiac troponin, emergency department, lcsh:Medicine, risk stratification, 030204 cardiovascular system & hematology, high sensitivity, Article, acute coronary syndrome, 03 medical and health sciences, 0302 clinical medicine, Copeptin, cardiac troponin, Internal medicine, medicine, 030212 general & internal medicine, business.industry, Proportional hazards model, Mortality rate, lcsh:R, copeptin, General Medicine, Emergency department, Omics, medicine.disease, humanities, Cohort, prognosis, business
Abstract

Aims: We aimed to assess the prognostic role of copeptin in patients presenting to the emergency department with acute symptoms and increased high-sensitivity cardiac troponin T. Methods: A total of 3890 patients presenting with acute symptoms to the emergency department of Heidelberg University Hospital were assessed for increased hs-cTnT (&gt, 14 ng/L) from three cohorts: the Heidelberg Acute Coronary Syndrome (ACS) Registry (n = 2477), the BIOPS Registry (n = 320), and the ACS OMICS Registry (n = 1093). In a pooled analysis, 1956 patients remained, comprising of 1600 patients with ACS and 356 patients with non-ACS. Results: Median follow-up was 1468 days in the ACS cohort and 709 days in the non-ACS cohort. Elevated copeptin levels (&gt, 10 pmol/L) were found in 1174 patients (60.0%) in the entire cohort (58.1% in ACS and 68.5% in non-ACS, respectively) and mortality rates were significantly higher than in patients with normal copeptin levels (29.0% vs. 10.7%, p &lt, 0.001). In a multivariate Cox regression, elevated copeptin was independently associated with all-cause death in the ACS (HR = 1.7, 1.3&ndash, 2.3, p = 0.002) and non-ACS cohort (HR = 2.7, 1.4&ndash, 5.0, p = 0.0018). Conclusion: Copeptin may aid in identifying patients at risk for adverse outcomes in patients with increased levels of hs-cTnT in ACS patients and in non-ACS conditions.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results